{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:01:58Z","timestamp":1793307718584,"version":"4.5.0"},"reference-count":103,"publisher":"Bentham Science Publishers Ltd.","issue":"19","funder":[{"DOI":"10.13039\/501100001411","name":"ICMR-SRF","doi-asserted-by":"publisher","award":["2021-15115\/PROTEOMICS-BMS"],"award-info":[{"award-number":["2021-15115\/PROTEOMICS-BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"DBT-TATA Innovation fellowship","doi-asserted-by":"publisher","award":["HRD-16012\/6\/2020-AFS-DBT"],"award-info":[{"award-number":["HRD-16012\/6\/2020-AFS-DBT"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite extensive research, there is an unmet need for developing disease-modifying\ntherapies for Parkinson\u2019s disease (PD). Failure of certain landmark clinical trials has highlighted\nthe need for a better understanding of the disease pathogenesis as well as identifying the hurdles\nin developing drug candidates and designing clinical trials. While adhering to these needs, several\npromising trials are currently underway with the hope of developing reliable targets. There is also\na need to conduct research on plant-based natural products and use them as therapeutic candidates\nfor PD. In this context, many studies have demonstrated the efficacy of medicinal plants and their\nprincipal phytochemicals. This review provides an update on the presently underway clinical trials\nwith a small emphasis on the disease modifying therapies that target small molecules, mitochondria,\nand oligodendrocytes. The role of ethnopharmacology-based approaches for treatment of PD\nhas also been discussed. The third aspect of the article considers the importance of nanomedicine\nin this area, including the use of liposomes and nanoparticles to provide a novel approach for the\ntreatment of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115680266314877241105051752","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:35:13Z","timestamp":1732754113000},"page":"2274-2287","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Strategies in Parkinson's Disease Therapeutics - A Need for Synergy of Ayurveda, Small Molecules and Nanoparticles aided Approaches"],"prefix":"10.2174","volume":"25","author":[{"given":"Shatabdi","family":"Choudhury","sequence":"first","affiliation":[{"name":"Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences,Bangalore, 560029; India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archi","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences,Bangalore, 560029; India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences,Bangalore, 560029; India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-9228","authenticated-orcid":true,"given":"Muchukunte Mukunda","family":"Srinivas Bharath","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences,Bangalore, 560029; India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Institute of Mental Health and Neurosciences,Bengaluru-560029; India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-3478","authenticated-orcid":true,"given":"Phalguni Anand","family":"Alladi","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences,Bangalore, 560029; India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1","volume":"201","author":"Braak H.","year":"2009","unstructured":"Braak H.; Del Tredici K.; Neuroanatomy and pathology of sporadic parkinson\u2019s disease. Adv Anat Embryol Cell Biol  2009,201,1-119","journal-title":"Adv Anat Embryol Cell Biol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"Vijiaratnam N.","year":"2021","unstructured":"Vijiaratnam N.; Simuni T.; Bandmann O.; Morris H.R.; Foltynie T.; Progress towards therapies for disease modification in parkinson\u2019s disease. Lancet Neurol  2021,20(7),559-572","journal-title":"Lancet Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","volume":"8","author":"Willis A.W.","year":"2022","unstructured":"Willis A.W.; Roberts E.; Beck J.C.; Fiske B.; Ross W.; Savica R.; Van Den Eeden S.K.; Tanner C.M.; Marras C.; Alcalay R.; Schwarzschild M.; Racette B.; Chen H.; Church T.; Wilson B.; Doria J.M.; Incidence of parkinson disease in North America. NPJ Parkinsons Dis  2022,8(1),170","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Ou Z.","year":"2021","unstructured":"Ou Z.; Pan J.; Tang S.; Duan D.; Yu D.; Nong H.; Wang Z.; Global trends in the incidence, prevalence, and years lived with disability of parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front Public Health  2021,9,776847","journal-title":"Front Public Health"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"Athauda D.","year":"2017","unstructured":"Athauda D.; Maclagan K.; Skene S.S.; Bajwa-Joseph M.; Letchford D.; Chowdhury K.; Hibbert S.; Budnik N.; Zampedri L.; Dickson J.; Li Y.; Aviles-Olmos I.; Warner T.T.; Limousin P.; Lees A.J.; Greig N.H.; Tebbs S.; Foltynie T.; Exenatide once weekly versus placebo in parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial. Lancet  2017,390(10103),1664-1675","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/mds.22974","volume":"25","author":"Eggert K.","year":"2010","unstructured":"Eggert K.; Squillacote D.; Barone P.; Dodel R.; Katzenschlager R.; Emre M.; Lees A.J.; Rascol O.; Poewe W.; Tolosa E.; Trenkwalder C.; Onofrj M.; Stocchi F.; Nappi G.; Kostic V.; Potic J.; Ruzicka E.; Oertel W.; Safety and efficacy of perampanel in advanced Parkinson\u2019s disease: A randomized, placebo-controlled study. Mov Disord  2010,25(7),896-905","journal-title":"Mov Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"LeWitt P.A.","year":"2015","unstructured":"LeWitt P.A.; Levodopa therapy for Parkinson\u2019s disease: Pharmacokinetics and pharmacodynamics. Mov Disord  2015,30(1),64-72","journal-title":"Mov Disord"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"Lees A.J.","year":"2017","unstructured":"Lees A.J.; Ferreira J.; Rascol O.; Poewe W.; Rocha J.F.; McCrory M.; Soares-da-Silva P.; Opicapone as adjunct to levodopa therapy in patients with parkinson disease and motor fluctuations: A randomized clinical trial. JAMA Neurol  2017,74(2),197-206","journal-title":"JAMA Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","volume":"51","author":"Rinne U.K.","year":"1998","unstructured":"Rinne U.K.; Larsen J.P.; Siden\u00c5.; Worm-Petersen J.; Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology  1998,51(5),1309-1314","journal-title":"Neurology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"Armstrong M.J.","year":"2020","unstructured":"Armstrong M.J.; Okun M.S.; Diagnosis and treatment of parkinson disease: A review. JAMA  2020,323(6),548-560","journal-title":"JAMA"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/mds.28599","volume":"36","author":"Nijhuis F.A.P.","year":"2021","unstructured":"Nijhuis F.A.P.; Esselink R.; de Bie R.M.A.; Groenewoud H.; Bloem B.R.; Post B.; Meinders M.J.; Translating evidence to advanced parkinson\u2019s disease patients: A systematic review and meta\u2010analysis. Mov Disord  2021,36(6),1293-1307","journal-title":"Mov Disord"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/pharmaceutics15030770","volume":"15","author":"Pardo-Moreno T.","year":"2023","unstructured":"Pardo-Moreno T.; Garc&#xED;a-Morales V.; Suleiman-Martos S.; Rivas-Dom&#xED;nguez A.; Mohamed-Mohamed H.; Ramos-Rodr&#xED;guez J.J.; Melguizo-Rodr&#xED;guez L.; Gonz&#xE1;lez-Acedo A.; Current treatments and new, tentative therapies for parkinson\u2019s disease. Pharmaceutics  2023,15(3),770","journal-title":"Pharmaceutics"},{"key":"ref=13","author":"Beaney A.","year":"2023","unstructured":"Beaney A.; Trials to watch: Pipeline parkinson\u2019s drugs could revolutionise treatment  Available from: \n https:\/\/www.clinicaltrialsarena.com\/features\/trials-to-watch-parkinsons-disease\/2023"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2174\/1871527322666230331121028","volume":"23","author":"Bezard E.","year":"2024","unstructured":"Bezard E.; Gray D.; Kozak R.; Leoni M.; Combs C.; Duvvuri S.; Rationale and development of Tavapadon, a D1\/D5-Selective partial dopamine agonist for the treatment of parkinson's disease. CNS Neurol Disord Drug Targets  2024,23(4),476-487","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.14336\/AD.2019.0805","volume":"11","author":"LeWitt P.A.","year":"2020","unstructured":"LeWitt P.A.; Kymes S.; Hauser R.A.; Parkinson disease and orthostatic hypotension in the elderly: Recognition and management of risk factors for falls. Aging Dis  2020,11(3),679-691","journal-title":"Aging Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neuint.2010.06.018","volume":"57","author":"Alladi P.A.","year":"2010","unstructured":"Alladi P.A.; Mahadevan A.; Vijayalakshmi K.; Muthane U.; Shankar S.K.; Raju T.R.; Ageing enhances\u03b1-synuclein, ubiquitin and endoplasmic reticular stress protein expression in the nigral neurons of Asian Indians. Neurochem Int  2010,57(5),530-539","journal-title":"Neurochem Int"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/JPD-202221","volume":"11","author":"Castonguay A.M.","year":"2021","unstructured":"Castonguay A.M.; Gravel C.; L&#xE9;vesque M.; Treating parkinson\u2019s disease with antibodies: Previous studies and future directions. J Parkinsons Dis  2021,11(1),71-92","journal-title":"J Parkinsons Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fnmol.2018.00109","volume":"11","author":"Suresh S.N.","year":"2018","unstructured":"Suresh S.N.; Chavalmane A.K.; Pillai M.; Ammanathan V.; Vidyadhara D.J.; Yarreiphang H.; Rai S.; Paul A.; Clement J.P.; Alladi P.A.; Manjithaya R.; Modulation of autophagy by a small molecule inverse agonist of ERR&#x3B1; is neuroprotective. Front Mol Neurosci  2018,11,109","journal-title":"Front Mol Neurosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/15548627.2017.1302045","volume":"13","author":"Suresh S.N.","year":"2017","unstructured":"Suresh S.N.; Chavalmane A.K.; Dj V.; Yarreiphang H.; Rai S.; Paul A.; Clement J.P.; Alladi P.A.; Manjithaya R.; A novel autophagy modulator 6-Bio ameliorates SNCA\/&#x3B1;-synuclein toxicity. Autophagy  2017,13(7),1221-1234","journal-title":"Autophagy"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ebiom.2019.10.036","volume":"50","author":"Sn S.","year":"2019","unstructured":"Sn S.; Pandurangi J.; Murumalla R.; Dj V.; Garimella L.; Acharya A.; Rai S.; Paul A.; Yarreiphang H.; Pillai M.S.; Giridharan M.; Clement J.P.; Alladi P.A.; Saiyed T.; Manjithaya R.; Small molecule modulator of aggrephagy regulates neuroinflammation to curb pathogenesis of neurodegeneration. EBioMedicine  2019,50,260-273","journal-title":"EBioMedicine"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"Wagner J.","year":"2013","unstructured":"Wagner J.; Ryazanov S.; Leonov A.; Levin J.; Shi S.; Schmidt F.; Prix C.; Pan-Montojo F.; Bertsch U.; Mitteregger-Kretzschmar G.; Geissen M.; Eiden M.; Leidel F.; Hirschberger T.; Deeg A.A.; Krauth J.J.; Zinth W.; Tavan P.; Pilger J.; Zweckstetter M.; Frank T.; B&#xE4;hr M.; Weishaupt J.H.; Uhr M.; Urlaub H.; Teichmann U.; Samwer M.; B&#xF6;tzel K.; Groschup M.; Kretzschmar H.; Griesinger C.; Giese A.; Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and parkinson\u2019s disease. Acta Neuropathol  2013,125(6),795-813","journal-title":"Acta Neuropathol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1038\/s41467-022-33252-6","volume":"13","author":"Emin D.","year":"2022","unstructured":"Emin D.; Zhang Y.P.; Lobanova E.; Miller A.; Li X.; Xia Z.; Dakin H.; Sideris D.I.; Lam J.Y.L.; Ranasinghe R.T.; Kouli A.; Zhao Y.; De S.; Knowles T.P.J.; Vendruscolo M.; Ruggeri F.S.; Aigbirhio F.I.; Williams-Gray C.H.; Klenerman D.; Small soluble\u03b1-synuclein aggregates are the toxic species in parkinson\u2019s disease. Nat Commun  2022,13(1),5512","journal-title":"Nat Commun"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","volume":"138","author":"Wegrzynowicz M.","year":"2019","unstructured":"Wegrzynowicz M.; Bar-On D.; Calo\u2019 L.; Anichtchik O.; Iovino M.; Xia J.; Ryazanov S.; Leonov A.; Giese A.; Dalley J.W.; Griesinger C.; Ashery U.; Spillantini M.G.; Depopulation of dense\u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new parkinson\u2019s disease model. Acta Neuropathol  2019,138(4),575-595","journal-title":"Acta Neuropathol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3233\/JPD-239901","volume":"13","author":"McFarthing K.","year":"2023","unstructured":"McFarthing K.; Buff S.; Rafaloff G.; Fiske B.; Mursaleen L.; Fuest R.; Wyse R. K.; Stott S. R.; Parkinson's disease drug therapies in the clinical trial pipeline: 2023 update. J Parkinsons Dis  2023,13(4),427-439","journal-title":"J Parkinsons Dis"},{"key":"ref=25","author":"D\u2019Urso G.","unstructured":"D\u2019Urso G.; Thomann A.E.; Anzures-Cabrera J.; Zinnhardt B.; Ricci B.; Marchesi M.; Machado V.; Mracsko E.Z.; Pavese N.; Marek K.; Brockmann K.; Simuni T.; Milani Muelhardt N.; Pagano G.; A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage parkinson\u2019s disease: Rationale and study design 2022 International Congress  111 RIVER ST, HOBOKEN, 2022  , Vol. 37, pp. S326-S326","journal-title":"2022 International Congress"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"103380","DOI":"10.1016\/j.ebiom.2021.103380","volume":"67","author":"Olson K.E.","year":"2021","unstructured":"Olson K.E.; Namminga K.L.; Lu Y.; Schwab A.D.; Thurston M.J.; Abdelmoaty M.M.; Kumar V.; Wojtkiewicz M.; Obaro H.; Santamaria P.; Mosley R.L.; Gendelman H.E.; Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of parkinson\u2019s disease. EBioMedicine  2021,67,103380","journal-title":"EBioMedicine"},{"key":"ref=27","first-page":"eaba1659","volume":"11","author":"Getchell K.","year":"2023","unstructured":"Getchell K.; Promising disease-modifying therapies in parkinson disease. Sci Transl Med  2023,11(520),eaba1659","journal-title":"Sci Transl Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cmet.2022.02.001","volume":"34","author":"Brakedal B.","year":"2022","unstructured":"Brakedal B.; D&#xF6;lle C.; Riemer F.; Ma Y.; Nido G.S.; Skeie G.O.; Craven A.R.; Schwarzlm&#xFC;ller T.; Brekke N.; Diab J.; Sverkeli L.; Skjeie V.; Varhaug K.; Tysnes O.B.; Peng S.; Haugarvoll K.; Ziegler M.; Gr&#xFC;ner R.; Eidelberg D.; Tzoulis C.; The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in parkinson\u2019s disease. Cell Metab  2022,34(3),396-407.e6","journal-title":"Cell Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"Nalls M.A.","year":"2019","unstructured":"Nalls M.A.; Blauwendraat C.; Vallerga C.L.; Heilbron K.; Bandres-Ciga S.; Chang D.; Tan M.; Kia D.A.; Noyce A.J.; Xue A.; Bras J.; Young E.; von Coelln R.; Sim&#xF3;n-S&#xE1;nchez J.; Schulte C.; Sharma M.; Krohn L.; Pihlstr&#xF8;m L.; Siitonen A.; Iwaki H.; Leonard H.; Faghri F.; Gibbs J.R.; Hernandez D.G.; Scholz S.W.; Botia J.A.; Martinez M.; Corvol J.C.; Lesage S.; Jankovic J.; Shulman L.M.; Sutherland M.; Tienari P.; Majamaa K.; Toft M.; Andreassen O.A.; Bangale T.; Brice A.; Yang J.; Gan-Or Z.; Gasser T.; Heutink P.; Shulman J.M.; Wood N.W.; Hinds D.A.; Hardy J.A.; Morris H.R.; Gratten J.; Visscher P.M.; Graham R.R.; Singleton A.B.; Adarmes-G&#xF3;mez A.D.; Aguilar M.; Aitkulova A.; Akhmetzhanov V.; Alcalay R.N.; Alvarez I.; Alvarez V.; Bandres-Ciga S.; Barrero F.J.; Bergareche Yarza J.A.; Bernal-Bernal I.; Billingsley K.; Blauwendraat C.; Blazquez M.; Bonilla-Toribio M.; Bot&#xED;a J.A.; Boungiorno M.T.; Bras J.; Brice A.; Brockmann K.; Bubb V.; Buiza-Rueda D.; C&#xE1;mara A.; Carrillo F.; Carri&#xF3;n-Claro M.; Cerdan D.; Chelban V.; Clarim&#xF3;n J.; Clarke C.; Compta Y.; Cookson M.R.; Corvol J-C.; Craig D.W.; Danjou F.; Diez-Fairen M.; Dols-Icardo O.; Duarte J.; Duran R.; Escamilla-Sevilla F.; Escott-Price V.; Ezquerra M.; Faghri F.; Feliz C.; Fern&#xE1;ndez M.; Fern&#xE1;ndez-Santiago R.; Finkbeiner S.; Foltynie T.; Gan-Or Z.; Garcia C.; Garc&#xED;a-Ruiz P.; Gasser T.; Gibbs J.R.; Gomez Heredia M.J.; G&#xF3;mez-Garre P.; Gonz&#xE1;lez M.M.; Gonzalez-Aramburu I.; Guelfi S.; Guerreiro R.; Hardy J.; Hassin-Baer S.; Hernandez D.G.; Heutink P.; Hoenicka J.; Holmans P.; Houlden H.; Infante J.; Iwaki H.; Jes&#xFA;s S.; Jimenez-Escrig A.; Kaishybayeva G.; Kaiyrzhanov R.; Karimova A.; Kia D.A.; Kinghorn K.J.; Koks S.; Krohn L.; Kulisevsky J.; Labrador-Espinosa M.A.; Leonard H.L.; Lesage S.; Lewis P.; Lopez-Sendon J.L.; Lovering R.; Lubbe S.; Lungu C.; Macias D.; Majamaa K.; Manzoni C.; Mar&#xED;n J.; Marinus J.; Marti M.J.; Martinez M.; Mart&#xED;nez Torres I.; Mart&#xED;nez-Castrillo J.C.; Mata M.; Mencacci N.E.; M&#xE9;ndez-del-Barrio C.; Middlehurst B.; M&#xED;nguez A.; Mir P.; Mok K.Y.; Morris H.R.; Mu&#xF1;oz E.; Nalls M.A.; Narendra D.; Noyce A.J.; Ojo O.O.; Okubadejo N.U.; Pagola A.G.; Pastor P.; Perez Errazquin F.; Peri&#xF1;&#xE1;n-Tocino T.; Pihlstrom L.; Plun-Favreau H.; Quinn J.; R\u2019Bibo L.; Reed X.; Rezola E.M.; Rizig M.; Rizzu P.; Robak L.; Rodriguez A.S.; Rouleau G.A.; Ruiz-Mart&#xED;nez J.; Ruz C.; Ryten M.; Sadykova D.; Scholz S.W.; Schreglmann S.; Schulte C.; Sharma M.; Shashkin C.; Shulman J.M.; Sierra M.; Siitonen A.; Sim&#xF3;n-S&#xE1;nchez J.; Singleton A.B.; Suarez-Sanmartin E.; Taba P.; Tabernero C.; Tan M.X.; Tartari J.P.; Tejera-Parrado C.; Toft M.; Tolosa E.; Trabzuni D.; Valldeoriola F.; van Hilten J.J.; Van Keuren-Jensen K.; Vargas-Gonz&#xE1;lez L.; Vela L.; Vives F.; Williams N.; Wood N.W.; Zharkinbekova N.; Zharmukhanov Z.; Zholdybayeva E.; Zimprich A.; Ylikotila P.; Shulman L.M.; von Coelln R.; Reich S.; Savitt J.; Agee M.; Alipanahi B.; Auton A.; Bell R.K.; Bryc K.; Elson S.L.; Fontanillas P.; Furlotte N.A.; Huber K.E.; Hicks B.; Jewett E.M.; Jiang Y.; Kleinman A.; Lin K-H.; Litterman N.K.; McCreight J.C.; McIntyre M.H.; McManus K.F.; Mountain J.L.; Noblin E.S.; Northover C.A.M.; Pitts S.J.; Poznik G.D.; Sathirapongsasuti J.F.; Shelton J.F.; Shringarpure S.; Tian C.; Tung J.; Vacic V.; Wang X.; Wilson C.H.; Anderson T.; Bentley S.; Dalrymple-Alford J.; Fowdar J.; Gratten J.; Halliday G.; Henders A.K.; Hickie I.; Kassam I.; Kennedy M.; Kwok J.; Lewis S.; Mellick G.; Montgomery G.; Pearson J.; Pitcher T.; Sidorenko J.; Silburn P.A.; Vallerga C.L.; Visscher P.M.; Wallace L.; Wray N.R.; Xue A.; Yang J.; Zhang F.; Identification of novel risk loci, causal insights, and heritable risk for parkinson\u2019s disease: A meta-analysis of genome-wide association studies. Lancet Neurol  2019,18(12),1091-1102","journal-title":"Lancet Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"Do J.","year":"2019","unstructured":"Do J.; McKinney C.; Sharma P.; Sidransky E.; Glucocerebrosidase and its relevance to parkinson disease. Mol Neurodegener  2019,14(1),36","journal-title":"Mol Neurodegener"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"Sidransky E.","year":"2009","unstructured":"Sidransky E.; Nalls M.A.; Aasly J.O.; Aharon-Peretz J.; Annesi G.; Barbosa E.R.; Bar-Shira A.; Berg D.; Bras J.; Brice A.; Chen C.M.; Clark L.N.; Condroyer C.; De Marco E.V.; D&#xFC;rr A.; Eblan M.J.; Fahn S.; Farrer M.J.; Fung H.C.; Gan-Or Z.; Gasser T.; Gershoni-Baruch R.; Giladi N.; Griffith A.; Gurevich T.; Januario C.; Kropp P.; Lang A.E.; Lee-Chen G.J.; Lesage S.; Marder K.; Mata I.F.; Mirelman A.; Mitsui J.; Mizuta I.; Nicoletti G.; Oliveira C.; Ottman R.; Orr-Urtreger A.; Pereira L.V.; Quattrone A.; Rogaeva E.; Rolfs A.; Rosenbaum H.; Rozenberg R.; Samii A.; Samaddar T.; Schulte C.; Sharma M.; Singleton A.; Spitz M.; Tan E.K.; Tayebi N.; Toda T.; Troiano A.R.; Tsuji S.; Wittstock M.; Wolfsberg T.G.; Wu Y.R.; Zabetian C.P.; Zhao Y.; Ziegler S.G.; Multicenter analysis of glucocerebrosidase mutations in parkinson\u2019s disease. N Engl J Med  2009,361(17),1651-1661","journal-title":"N Engl J Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40263-018-0548-y","volume":"32","author":"Athauda D.","year":"2018","unstructured":"Athauda D.; Foltynie T.; Drug repurposing in parkinson\u2019s disease. CNS Drugs  2018,32(8),747-761","journal-title":"CNS Drugs"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"104021","DOI":"10.1016\/j.ebiom.2022.104021","volume":"80","author":"Levin J.","year":"2022","unstructured":"Levin J.; Sing N.; Melbourne S.; Morgan A.; Mariner C.; Spillantini M.G.; Wegrzynowicz M.; Dalley J.W.; Langer S.; Ryazanov S.; Leonov A.; Griesinger C.; Schmidt F.; Weckbecker D.; Prager K.; Matthias T.; Giese A.; Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine  2022,80,104021","journal-title":"EBioMedicine"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature11314","volume":"487","author":"Lee Y.","year":"2012","unstructured":"Lee Y.; Morrison B.M.; Li Y.; Lengacher S.; Farah M.H.; Hoffman P.N.; Liu Y.; Tsingalia A.; Jin L.; Zhang P.W.; Pellerin L.; Magistretti P.J.; Rothstein J.D.; Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature  2012,487(7408),443-448","journal-title":"Nature"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/glia.22432","volume":"61","author":"Behrendt G.","year":"2013","unstructured":"Behrendt G.; Baer K.; Buffo A.; Curtis M.A.; Faull R.L.; Rees M.I.; G&#xF6;tz M.; Dimou L.; Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia  2013,61(2),273-286","journal-title":"Glia"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","volume":"234","author":"Ubhi K.","year":"2012","unstructured":"Ubhi K.; Inglis C.; Mante M.; Patrick C.; Adame A.; Spencer B.; Rockenstein E.; May V.; Winkler J.; Masliah E.; Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of\u03b1-synucleinopathy. Exp Neurol  2012,234(2),405-416","journal-title":"Exp Neurol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1523\/JNEUROSCI.0567-10.2010","volume":"30","author":"Ubhi K.","year":"2010","unstructured":"Ubhi K.; Rockenstein E.; Mante M.; Inglis C.; Adame A.; Patrick C.; Whitney K.; Masliah E.; Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci  2010,30(18),6236-6246","journal-title":"J Neurosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/0271678X19830791","volume":"40","author":"Dai X.","year":"2020","unstructured":"Dai X.; Chen J.; Xu F.; Zhao J.; Cai W.; Sun Z.; Hitchens T.K.; Foley L.M.; Leak R.K.; Chen J.; Hu X.; TGF&#x3B1; preserves oligodendrocyte lineage cells and improves white matter integrity after cerebral ischemia. J Cereb Blood Flow Metab  2020,40(3),639-655","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nn.3990","volume":"18","author":"Zonouzi M.","year":"2015","unstructured":"Zonouzi M.; Scafidi J.; Li P.; McEllin B.; Edwards J.; Dupree J.L.; Harvey L.; Sun D.; H&#xFC;bner C.A.; Cull-Candy S.G.; Farrant M.; Gallo V.; GABAergic regulation of cerebellar NG2 cell development is altered in perinatal white matter injury. Nat Neurosci  2015,18(5),674-682","journal-title":"Nat Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1523\/JNEUROSCI.1862-17.2018","volume":"38","author":"Welliver R.R.","year":"2018","unstructured":"Welliver R.R.; Polanco J.J.; Seidman R.A.; Sinha A.K.; O\u2019Bara M.A.; Khaku Z.M.; Santiago Gonz&#xE1;lez D.A.; Nishiyama A.; Wess J.; Feltri M.L.; Paez P.M.; Sim F.J.; Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells. J Neurosci  2018,38(31),6921-6932","journal-title":"J Neurosci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.brainres.2014.08.046","volume":"1586","author":"Zhu Y.","year":"2014","unstructured":"Zhu Y.; Wendler C.C.; Shi O.; Rivkees S.A.; Diazoxide promotes oligodendrocyte differentiation in neonatal brain in normoxia and chronic sublethal hypoxia. Brain Res  2014,1586,64-72","journal-title":"Brain Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.ebiom.2021.103276","volume":"65","author":"Manousi A.","year":"2021","unstructured":"Manousi A.; G&#xF6;ttle P.; Reiche L.; Cui Q.L.; Healy L.M.; Akkermann R.; Gruchot J.; Schira-Heinen J.; Antel J.P.; Hartung H.P.; K&#xFC;ry P.; Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence. EBioMedicine  2021,65,103276","journal-title":"EBioMedicine"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fncel.2014.00384","volume":"8","author":"Steiner J.","year":"2014","unstructured":"Steiner J.; Martins-de-Souza D.; Schiltz K.; Sarnyai Z.; Westphal S.; Isermann B.; Dobrowolny H.; Turck C.W.; Bogerts B.; Bernstein H.G.; Horvath T.L.; Schild L.; Keilhoff G.; Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. Front Cell Neurosci  2014,8,384","journal-title":"Front Cell Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"Beal M.F.","year":"2014","unstructured":"Beal M.F.; Oakes D.; Shoulson I.; Henchcliffe C.; Galpern W.R.; Haas R.; Juncos J.L.; Nutt J.G.; Voss T.S.; Ravina B.; Shults C.M.; Helles K.; Snively V.; Lew M.F.; Griebner B.; Watts A.; Gao S.; Pourcher E.; Bond L.; Kompoliti K.; Agarwal P.; Sia C.; Jog M.; Cole L.; Sultana M.; Kurlan R.; Richard I.; Deeley C.; Waters C.H.; Figueroa A.; Arkun A.; Brodsky M.; Ondo W.G.; Hunter C.B.; Jimenez-Shahed J.; Palao A.; Miyasaki J.M.; So J.; Tetrud J.; Reys L.; Smith K.; Singer C.; Blenke A.; Russell D.S.; Cotto C.; Friedman J.H.; Lannon M.; Zhang L.; Drasby E.; Kumar R.; Subramanian T.; Ford D.S.; Grimes D.A.; Cote D.; Conway J.; Siderowf A.D.; Evatt M.L.; Sommerfeld B.; Lieberman A.N.; Okun M.S.; Rodriguez R.L.; Merritt S.; Swartz C.L.; Martin W.R.W.; King P.; Stover N.; Guthrie S.; Watts R.L.; Ahmed A.; Fernandez H.H.; Winters A.; Mari Z.; Dawson T.M.; Dunlop B.; Feigin A.S.; Shannon B.; Nirenberg M.J.; Ogg M.; Ellias S.A.; Thomas C.A.; Frei K.; Bodis-Wollner I.; Glazman S.; Mayer T.; Hauser R.A.; Pahwa R.; Langhammer A.; Ranawaya R.; Derwent L.; Sethi K.D.; Farrow B.; Prakash R.; Litvan I.; Robinson A.; Sahay A.; Gartner M.; Hinson V.K.; Markind S.; Pelikan M.; Perlmutter J.S.; Hartlein J.; Molho E.; Evans S.; Adler C.H.; Duffy A.; Lind M.; Elmer L.; Davis K.; Spears J.; Wilson S.; Leehey M.A.; Hermanowicz N.; Niswonger S.; Shill H.A.; Obradov S.; Rajput A.; Cowper M.; Lessig S.; Song D.; Fontaine D.; Zadikoff C.; Williams K.; Blindauer K.A.; Bergholte J.; Propsom C.S.; Stacy M.A.; Field J.; Mihaila D.; Chilton M.; Uc E.Y.; Sieren J.; Simon D.K.; Kraics L.; Silver A.; Boyd J.T.; Hamill R.W.; Ingvoldstad C.; Young J.; Thomas K.; Kostyk S.K.; Wojcieszek J.; Pfeiffer R.F.; Panisset M.; Beland M.; Reich S.G.; Cines M.; Zappala N.; Rivest J.; Zweig R.; Lumina L.P.; Hilliard C.L.; Grill S.; Kellermann M.; Tuite P.; Rolandelli S.; Kang U.J.; Young J.; Rao J.; Cook M.M.; Severt L.; Boyar K.; A randomized clinical trial of high-dosage coenzyme Q10 in early parkinson disease: No evidence of benefit. JAMA Neurol  2014,71(5),543-552","journal-title":"JAMA Neurol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.7326\/M19-2534","volume":"172","year":"2020","unstructured":"Isradipine versus placebo in early Parkinson disease: A randomized trial. Ann Intern Med  2020,172(9),591-598","journal-title":"Ann Intern Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/13880209.2019.1618344","volume":"57","author":"Rabiei Z.","year":"2019","unstructured":"Rabiei Z.; Solati K.; Amini-Khoei H.; Phytotherapy in treatment of parkinson\u2019s disease: A review. Pharm Biol  2019,57(1),355-362","journal-title":"Pharm Biol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jchemneu.2015.12.002","volume":"71","author":"Rai S.N.","year":"2016","unstructured":"Rai S.N.; Yadav S.K.; Singh D.; Singh S.P.; Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced parkinsonian mouse model. J Chem Neuroanat  2016,71,41-49","journal-title":"J Chem Neuroanat"},{"key":"ref=48","first-page":"441","volume":"3","author":"Yadav S.K.","year":"2016","unstructured":"Yadav S.K.; Rai S.N.; Singh S.P.; Mucuna pruriens shows neuroprotective effect by inhibiting apoptotic pathways of dopaminergic neurons in the paraquat mouse model of parkinsonism. Eur J Pharm Med Res  2016,3,441-451","journal-title":"Eur J Pharm Med Res"},{"key":"ref=49","volume":"1","author":"Sathiyanarayanan L.","year":"2007","unstructured":"Sathiyanarayanan L.; Arulmozhi S.; Mucuna pruriens Linn.-A comprehensive review. Pharmacogn Rev  2007,1(1)","journal-title":"Pharmacogn Rev"},{"key":"ref=50","first-page":"73","volume":"3","author":"Adepoju G.K.A.","year":"2009","unstructured":"Adepoju G.K.A.; Odubena O.O.; Effect of Mucuna pruriens on some haematological and biochemical parameters. J Med Plants Res  2009,3(2),73-76","journal-title":"J Med Plants Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.neuint.2013.03.015","volume":"62","author":"Yadav S.K.","year":"2013","unstructured":"Yadav S.K.; Prakash J.; Chouhan S.; Singh S.P.; Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced parkinsonian mouse model. Neurochem Int  2013,62(8),1039-1047","journal-title":"Neurochem Int"},{"key":"ref=52","first-page":"689","volume":"3","author":"Bhaskar A.","year":"2011","unstructured":"Bhaskar A.; Nithya V.; Vidhya V.G.; Phytochemical evaluation by GC-MS and antihyperglycemic activity of Mucuna pruriens on streptozotocin induced diabetes in rats. J Chem Pharm Res  2011,3(5),689-696","journal-title":"J Chem Pharm Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.4314\/tjpr.v20i6.14","volume":"20","author":"Nayak V.S.","year":"2022","unstructured":"Nayak V.S.; Pai K.S.R.; Nayak S.S.; Kumar N.; Bangera H.; Effect of Mucuna pruriens (Linn.) on global cerebral Ischemia-induced motor incoordination. Trop J Pharm Res  2022,20(6),1193-1198","journal-title":"Trop J Pharm Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e110802","DOI":"10.1371\/journal.pone.0110802","volume":"9","author":"Poddighe S.","year":"2014","unstructured":"Poddighe S.; De Rose F.; Marotta R.; Ruffilli R.; Fanti M.; Secci P.P.; Mostallino M.C.; Setzu M.D.; Zuncheddu M.A.; Collu I.; Solla P.; Marrosu F.; Kasture S.; Acquas E.; Liscia A.; Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of parkinson\u2019s disease. PLoS One  2014,9(10),e110802","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fnagi.2017.00421","volume":"9","author":"Rai S.N.","year":"2017","unstructured":"Rai S.N.; Birla H.; Singh S.S.; Zahra W.; Patil R.R.; Jadhav J.P.; Gedda M.R.; Singh S.P.; Mucuna pruriens protects against MPTP intoxicated neuroinflammation in parkinson\u2019s disease through NF-&#x3BA;B\/pAKT signaling pathways. Front Aging Neurosci  2017,9,421","journal-title":"Front Aging Neurosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchemneu.2016.11.009","volume":"80","author":"Yadav S.K.","year":"2017","unstructured":"Yadav S.K.; Rai S.N.; Singh S.P.; Mucuna pruriens reduces inducible nitric oxide synthase expression in parkinsonian mice model. J Chem Neuroanat  2017,80,1-10","journal-title":"J Chem Neuroanat"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2013.12.001","volume":"65","author":"Yadav S.K.","year":"2014","unstructured":"Yadav S.K.; Prakash J.; Chouhan S.; Westfall S.; Verma M.; Singh T.D.; Singh S.P.; Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model. Neurochem Int  2014,65,1-13","journal-title":"Neurochem Int"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coph.2015.10.006","volume":"26","author":"Olson K.E.","year":"2016","unstructured":"Olson K.E.; Gendelman H.E.; Immunomodulation as a neuroprotective and therapeutic strategy for parkinson\u2019s disease. Curr Opin Pharmacol  2016,26,87-95","journal-title":"Curr Opin Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/ptr.2219","volume":"21","author":"Tharakan B.","year":"2007","unstructured":"Tharakan B.; Dhanasekaran M.; Mize-Berge J.; Manyam B.V.; Anti\u2010parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage. Phytother Res  2007,21(12),1124-1126","journal-title":"Phytother Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ptr.2109","volume":"22","author":"Dhanasekaran M.","year":"2008","unstructured":"Dhanasekaran M.; Tharakan B.; Manyam B.V.; Antiparkinson drug \u2013 Mucuna pruriens shows antioxidant and metal chelating activity. Phytother Res  2008,22(1),6-11","journal-title":"Phytother Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/acm.1995.1.249","volume":"1","year":"1995","unstructured":"An alternative medicine treatment for parkinson\u2019s disease: Results of a multicenter clinical trial. J Altern Complement Med  1995,1(3),249-255","journal-title":"J Altern Complement Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mds.870050112","volume":"5","author":"Manyam B.V.","year":"1990","unstructured":"Manyam B.V.; Paralysis agitans and levodopa in\u201cAyurveda&#x201D;: Ancient Indian medical treatise. Mov Disord  1990,5(1),47-48","journal-title":"Mov Disord"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1136\/jnnp.2003.028761","volume":"75","author":"Katzenschlager R.","year":"2004","unstructured":"Katzenschlager R.; Evans A.; Manson A.; Patsalos P.N.; Ratnaraj N.; Watt H.; Timmermann L.; Van der Giessen R.; Lees A.J.; Mucuna pruriens in parkinson\u2019s disease: A double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry  2004,75(12),1672-1677","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/WNL.0000000000004175","volume":"89","author":"Cilia R.","year":"2017","unstructured":"Cilia R.; Laguna J.; Cassani E.; Cereda E.; Pozzi N.G.; Isaias I.U.; Contin M.; Barichella M.; Pezzoli G.; Mucuna pruriens in parkinson disease. Neurology  2017,89(5),432-438","journal-title":"Neurology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.parkreldis.2018.01.014","volume":"49","author":"Cilia R.","year":"2018","unstructured":"Cilia R.; Laguna J.; Cassani E.; Cereda E.; Raspini B.; Barichella M.; Pezzoli G.; Daily intake of Mucuna pruriens in advanced Parkinson\u2019s disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord  2018,49,60-66","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.brainres.2011.10.030","volume":"1429","author":"Li Y.","year":"2012","unstructured":"Li Y.; Zhuang P.; Shen B.; Zhang Y.; Shen J.; Baicalin promotes neuronal differentiation of neural stem\/progenitor cells through modulating p-stat3 and bHLH family protein expression. Brain Res  2012,1429,36-42","journal-title":"Brain Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neulet.2008.05.116","volume":"441","author":"Cheng Y.","year":"2008","unstructured":"Cheng Y.; He G.; Mu X.; Zhang T.; Li X.; Hu J.; Xu B.; Du G.; Neuroprotective effect of baicalein against MPTP neurotoxicity: Behavioral, biochemical and immunohistochemical profile. Neurosci Lett  2008,441(1),16-20","journal-title":"Neurosci Lett"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.pbb.2009.03.008","volume":"92","author":"Mu X.","year":"2009","unstructured":"Mu X.; He G.; Cheng Y.; Li X.; Xu B.; Du G.; Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav  2009,92(4),642-648","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ptr.1976","volume":"20","author":"Naik S.R.","year":"2006","unstructured":"Naik S.R.; Pilgaonkar V.W.; Panda V.S.; Evaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brain. Phytother Res  2006,20(11),1013-1016","journal-title":"Phytother Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1017\/cjn.2017.268","volume":"45","author":"Kuang S.","year":"2018","unstructured":"Kuang S.; Yang L.; Rao Z.; Zhong Z.; Li J.; Zhong H.; Dai L.; Tang X.; Effects of Ginkgo biloba extract on A53T\u03b1-synuclein transgenic mouse models of parkinson\u2019s disease. Can J Neurol Sci  2018,45(2),182-187","journal-title":"Can J Neurol Sci"},{"key":"ref=71","first-page":"193","volume":"12","author":"Abdel-Salam O.M.","year":"2013","unstructured":"Abdel-Salam O.M.; Salem N.A.; El-Sayed El-Shamarka M.; Al-Said Ahmed N.; Seid Hussein J.; El-Khyat Z.A.; Cannabis-induced impairment of learning and memory: Effect of different nootropic drugs. EXCLI J  2013,12,193-214","journal-title":"EXCLI J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/8288818","volume":"2022","author":"Noor-E-Tabassum","year":"2022","unstructured":"Noor-E-Tabassum ; Das R.; Lami M.S.; Chakraborty A.J.; Mitra S.; Tallei T.E.; Idroes R.; Mohamed A.A.R.; Hossain M.J.; Dhama K.; Mostafa-Hedeab G.; Emran T.B.; Ginkgo biloba: A treasure of functional phytochemicals with multimedicinal applications. Evid Based Complement Alternat Med  2022,2022,1-30","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/ars.2006.1479","volume":"9","author":"Mythri R.B.","year":"2007","unstructured":"Mythri R.B.; Jagatha B.; Pradhan N.; Andersen J.; Bharath M.M.S.; Mitochondrial complex I inhibition in parkinson\u2019s disease: How can curcumin protect mitochondria? Antioxid Redox Signal  2007,9(3),399-408","journal-title":"Antioxid Redox Signal"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11010-010-0621-4","volume":"347","author":"Mythri R.B.","year":"2011","unstructured":"Mythri R.B.; Harish G.; Dubey S.K.; Misra K.; Srinivas Bharath M.M.; Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: Implications for Parkinson\u2019s disease. Mol Cell Biochem  2011,347(1-2),135-143","journal-title":"Mol Cell Biochem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/138161212798918995","volume":"18","author":"Mythri R.B.","year":"2012","unstructured":"Mythri R.B.; Bharath M.M.; Curcumin: A potential neuroprotective agent in parkinson\u2019s disease. Curr Pharm Des  2012,18(1),91-99","journal-title":"Curr Pharm Des"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.freeradbiomed.2007.11.011","volume":"44","author":"Jagatha B.","year":"2008","unstructured":"Jagatha B.; Mythri R.B.; Vali S.; Bharath M.M.S.; Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for parkinson\u2019s disease explained via in silico studies. Free Radic Biol Med  2008,44(5),907-917","journal-title":"Free Radic Biol Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.bmc.2010.02.029","volume":"18","author":"Harish G.","year":"2010","unstructured":"Harish G.; Venkateshappa C.; Mythri R.B.; Dubey S.K.; Mishra K.; Singh N.; Vali S.; Bharath M.M.S.; Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for parkinson\u2019s disease. Bioorg Med Chem  2010,18(7),2631-2638","journal-title":"Bioorg Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2174\/092986732102131206115810","volume":"21","author":"Marchiani A.","year":"2013","unstructured":"Marchiani A.; Rozzo C.; Fadda A.; Delogu G.; Ruzza P.; Curcumin and curcumin-like molecules: From spice to drugs. Curr Med Chem  2013,21(2),204-222","journal-title":"Curr Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.neuroscience.2008.11.051","volume":"159","author":"Alladi P.A.","year":"2009","unstructured":"Alladi P.A.; Mahadevan A.; Yasha T.C.; Raju T.R.; Shankar S.K.; Muthane U.; Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: Relevance to lower incidence of parkinson\u2019s disease. Neuroscience  2009,159(1),236-245","journal-title":"Neuroscience"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2202-11-57","volume":"11","author":"Wang M.S.","year":"2010","unstructured":"Wang M.S.; Boddapati S.; Emadi S.; Sierks M.R.; Curcumin reduces\u03b1-synuclein induced cytotoxicity in parkinson\u2019s disease cell model. BMC Neurosci  2010,11(1),57","journal-title":"BMC Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11481-012-9363-2","volume":"7","author":"Ojha R.P.","year":"2012","unstructured":"Ojha R.P.; Rastogi M.; Devi B.P.; Agrawal A.; Dubey G.P.; Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of parkinson\u2019s disease. J Neuroimmune Pharmacol  2012,7(3),609-618","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2047-9158-1-16","volume":"1","author":"Pan J.","year":"2012","unstructured":"Pan J.; Li H.; Ma J.F.; Tan Y.Y.; Xiao Q.; Ding J.Q.; Chen S.D.; Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of parkinson\u2019s disease through suppressing mitochondria dysfunction. Transl Neurodegener  2012,1(1),16","journal-title":"Transl Neurodegener"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/00207454.2011.648760","volume":"122","author":"Tripanichkul W.","year":"2012","unstructured":"Tripanichkul W.; Jaroensuppaperch E.; Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model. Int J Neurosci  2012,122(5),263-270","journal-title":"Int J Neurosci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/jcp.0b013e318160862c","volume":"28","author":"Baum L.","year":"2008","unstructured":"Baum L.; Lam C.W.K.; Cheung S.K.K.; Kwok T.; Lui V.; Tsoh J.; Lam L.; Leung V.; Hui E.; Ng C.; Woo J.; Chiu H.F.K.; Goggins W.B.; Zee B.C.Y.; Cheng K.F.; Fong C.Y.S.; Wong A.; Mok H.; Chow M.S.S.; Ho P.C.; Ip S.P.; Ho C.S.; Yu X.W.; Lai C.Y.L.; Chan M.H.; Szeto S.; Chan I.H.S.; Mok V.; Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with alzheimer disease. J Clin Psychopharmacol  2008,28(1),110-113","journal-title":"J Clin Psychopharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/alzrt146","volume":"4","author":"Ringman J.M.","year":"2012","unstructured":"Ringman J.M.; Frautschy S.A.; Teng E.; Begum A.N.; Bardens J.; Beigi M.; Gylys K.H.; Badmaev V.; Heath D.D.; Apostolova L.G.; Porter V.; Vanek Z.; Marshall G.A.; Hellemann G.; Sugar C.; Masterman D.L.; Montine T.J.; Cummings J.L.; Cole G.M.; Oral curcumin for alzheimer\u2019s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther  2012,4(5),43","journal-title":"Alzheimers Res Ther"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1001\/jama.2009.1913","volume":"302","author":"Snitz B.E.","year":"2009","unstructured":"Snitz B.E.; O\u2019Meara E.S.; Carlson M.C.; Arnold A.M.; Ives D.G.; Rapp S.R.; Saxton J.; Lopez O.L.; Dunn L.O.; Sink K.M.; DeKosky S.T.; Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA  2009,302(24),2663-2670","journal-title":"JAMA"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"129698","DOI":"10.1016\/j.molstruc.2020.129698","volume":"1231","author":"Ghazy E.","year":"2021","unstructured":"Ghazy E.; Rahdar A.; Barani M.; Kyzas G.Z.; Nanomaterials for parkinson disease: Recent progress. J Mol Struct  2021,1231,129698","journal-title":"J Mol Struct"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/bs.irn.2016.06.007","volume":"130","author":"Sintov A.C.","year":"2016","unstructured":"Sintov A.C.; Velasco-Aguirre C.; Gallardo-Toledo E.; Araya E.; Kogan M.J.; Metal nanoparticles as targeted carriers circumventing the blood\u2013brain barrier. Int Rev Neurobiol  2016,130,199-227","journal-title":"Int Rev Neurobiol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cncr.22035","volume":"107","author":"Cuenca A.G.","year":"2006","unstructured":"Cuenca A.G.; Jiang H.; Hochwald S.N.; Delano M.; Cance W.G.; Grobmyer S.R.; Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer  2006,107(3),459-466","journal-title":"Cancer"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12868-021-00655-y","volume":"22","author":"Razavi S.","year":"2021","unstructured":"Razavi S.; Jahromi M.; Vatankhah E.; Seyedebrahimi R.; Differential effects of rat ADSCs encapsulation in fibrin matrix and combination delivery of BDNF and Gold nanoparticles on peripheral nerve regeneration. BMC Neurosci  2021,22(1),50","journal-title":"BMC Neurosci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/NSA.S3788","volume":"1","author":"Cai W.","year":"2008","unstructured":"Cai W.; Gao T.; Hong H.; Sun J.; Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl  2008,1,17-32","journal-title":"Nanotechnol Sci Appl"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.04.026","volume":"379","author":"Huynh N.T.","year":"2009","unstructured":"Huynh N.T.; Passirani C.; Saulnier P.; Beno&#xEE;t J.P.; Lipid nanocapsules: A new platform for nanomedicine. Int J Pharm  2009,379(2),201-209","journal-title":"Int J Pharm"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.chemphyslip.2013.10.011","volume":"177","author":"Patil Y.P.","year":"2014","unstructured":"Patil Y.P.; Jadhav S.; Novel methods for liposome preparation. Chem Phys Lipids  2014,177,8-18","journal-title":"Chem Phys Lipids"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jconrel.2015.07.030","volume":"219","author":"Batrakova E.V.","year":"2015","unstructured":"Batrakova E.V.; Kim M.S.; Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release  2015,219,396-405","journal-title":"J Control Release"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"Pardridge W.M.","year":"2012","unstructured":"Pardridge W.M.; Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab  2012,32(11),1959-1972","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0006-8993(00)02758-X","volume":"879","author":"Kageyama T.","year":"2000","unstructured":"Kageyama T.; Nakamura M.; Matsuo A.; Yamasaki Y.; Takakura Y.; Hashida M.; Kanai Y.; Naito M.; Tsuruo T.; Minato N.; Shimohama S.; The 4F2hc\/LAT1 complex transports l-DOPA across the blood\u2013brain barrier. Brain Res  2000,879(1-2),115-121","journal-title":"Brain Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","volume":"23","author":"Kulkarni A.D.","year":"2015","unstructured":"Kulkarni A.D.; Vanjari Y.H.; Sancheti K.H.; Belgamwar V.S.; Surana S.J.; Pardeshi C.V.; Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: A mini review. J Drug Target  2015,23(9),775-788","journal-title":"J Drug Target"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","volume":"48","author":"Md S.","year":"2013","unstructured":"Md S.; Khan R.A.; Mustafa G.; Chuttani K.; Baboota S.; Sahni J.K.; Ali J.; Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model. Eur J Pharm Sci  2013,48(3),393-405","journal-title":"Eur J Pharm Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.nano.2014.12.014","volume":"11","author":"Gendelman H.E.","year":"2015","unstructured":"Gendelman H.E.; Anantharam V.; Bronich T.; Ghaisas S.; Jin H.; Kanthasamy A.G.; Liu X.; McMillan J.; Mosley R.L.; Narasimhan B.; Mallapragada S.K.; Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine  2015,11(3),751-767","journal-title":"Nanomedicine"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules25092193","volume":"25","author":"Yetisgin A.A.","year":"2020","unstructured":"Yetisgin A.A.; Cetinel S.; Zuvin M.; Kosar A.; Kutlu O.; Therapeutic nanoparticles and their targeted delivery applications. Molecules  2020,25(9),2193","journal-title":"Molecules"},{"key":"ref=101","first-page":"172","volume":"900","author":"Niu J.M.","year":"2014","unstructured":"Niu J.M.; Zheng Z.G.; Effect of temperature on Fe3O4 magnetic nanoparticles prepared by coprecipitation method. Adv Mat Res  2014,900,172-176","journal-title":"Adv Mat Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.nanoen.2018.06.064","volume":"51","author":"Kim D.H.","year":"2018","unstructured":"Kim D.H.; Kim T.W.; Ultrahigh-luminosity white-light-emitting devices based on edge functionalized graphene quantum dots. Nano Energy  2018,51,199-205","journal-title":"Nano Energy"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2217\/nnm.10.7","volume":"5","author":"Brynskikh A.M.","year":"2010","unstructured":"Brynskikh A.M.; Zhao Y.; Mosley R.L.; Li S.; Boska M.D.; Klyachko N.L.; Kabanov A.V.; Gendelman H.E.; Batrakova E.V.; Macrophage delivery of therapeutic nanozymes in a murine model of parkinson\u2019s disease. Nanomedicine (Lond)  2010,5(3),379-396","journal-title":"Nanomedicine (Lond)"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680266314877241105051752","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/236597\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680266314877241105051752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T04:36:40Z","timestamp":1763095000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/236597\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":103,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115680266314877241105051752","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}